



Actinic Keratosis Agents Step Therapy Guidelines

Affected Medication(s)
• Diclofenac 3% topical gel • Carac (fluorouracil) 0.5% topical cream • Fluorouracil 0.5% topical cream • Tolak (fluorouracil) 4% topical cream • Fluoroplex (fluorouracil) 1% topical cream • Klisyri (tirbanibulin) topical ointment • Zyclara (imiquimod) topical cream pack • Imiquimod 3.75% topical cream • Zyclara (imiquimod) topical cream metered dose pump • Imiquimod 3.75% topical cream pump
Step Therapy Requirements
Step 1 Drug(s): • Imiquimod 5% topical cream pack • Fluorouracil 5% topical cream
Step Therapy Criteria
1. Prescription claim for ONE Step 1 Drug(s) within the past 180 days (Note: 90 days of claims history required for authorization) a. If yes, approve for 12 months b. If no, continue to #2 2. If no claim history of Step 1 Drug(s), documentation of trial, intolerance or contraindication to ONE Step 1 Drug is required a. If yes, approve for 12 months b. If no, clinical review required

Note:

Medication step therapy guidelines are used as a basis for making coverage decisions and do not serve as medical advice. Coverage of medications is subject to plan provisions. Additional coverage restrictions not listed in the guidelines may apply.



Amrix® (cyclobenzaprine HCl) Step Therapy Guidelines

Affected Medication(s)	
- Amrix (cyclobenzaprine HCl) ER oral capsule - Cyclobenzaprine ER oral capsule	
Step Therapy Requirements	
Step 1 Drug(s): Cyclobenzaprine HCl oral tablet	
Step Therapy Criteria	
- Prescription claim for ONE Step 1 Drug(s) within the past 180 days (Note: 90 days of claims history required for authorization) - If yes, approve for 12 months - If no, continue to #2 - If no claim history of Step 1 Drug(s), documentation of trial, intolerance or contraindication to ONE Step 1 Drug is required - If yes, approve for 12 months - If no, clinical review required	

Note:

Medication step therapy guidelines are used as a basis for making coverage decisions and do not serve as medical advice. Coverage of medications is subject to plan provisions. Additional coverage restrictions not listed in the guidelines may apply.



Anticoagulant Agents Step Therapy Guidelines

Affected Medication(s)
- dabigatran oral capsule - Pradaxa (dabigatran etexilate mesylate) oral capsule - Savaysa (edoxaban tosylate) oral tablet
Step Therapy Requirements
Step 1 Drug(s): - Eliquis (apixaban) oral tablet - rivaroxaban oral tablet - Xarelto (rivaroxaban) oral tablet
Step Therapy Criteria
- Prescription claim for TWO Step 1 Drugs within the past 180 days (Note: 90 days of claims history required for authorization) - If yes, approve for 12 months - If no, continue to #2 - If no claim history of Step 1 Drug(s), documentation of trial, intolerance or contraindication to TWO Step 1 Drugs is required - If yes, approve for 12 months - If no, clinical review required

Note:

Medication step therapy guidelines are used as a basis for making coverage decisions and do not serve as medical advice. Coverage of medications is subject to plan provisions. Additional coverage restrictions not listed in the guidelines may apply.



Antidepressant Agents Step Therapy Guidelines

Affected Medication(s)
• Bupropion XL 450 mg oral tablet • Desvenlafaxine ER oral tablet • Fetzima (levomilnacipran HCl) SA oral capsule • Forfivo XL (bupropion HCl) ER oral tablet • Fluvoxamine ER oral capsule • Imipramine pamoate oral capsule • Marplan (isocarboxazid) oral tablet • Trimipramine maleate oral capsule • Trintellix (vortioxetine hydrobromide) oral tablet • Venlafaxine ER oral tablet
Step Therapy Requirements
Step 1 Drug(s): • Citalopram hydrobromide oral tablet • Desvenlafaxine succinate ER oral tablet • Duloxetine HCl oral capsule • Escitalopram oxalate oral tablet • Fluoxetine HCl oral tablet • Fluoxetine HCl oral capsule • Fluvoxamine maleate oral tablet • Paroxetine HCl oral tablet • Sertraline HCl oral tablet • Venlafaxine HCl oral tablet • Venlafaxine ER oral capsule
Step Therapy Criteria
1. Prescription claim for TWO Step 1 Drug(s) within the past 180 days (Note: 90 days of claims history required for authorization) a. If yes, approve for 12 months b. If no, continue to #2 2. If no claim history of Step 1 Drug(s), documentation of trial, intolerance or contraindication to TWO Step 1 Drug is required a. If yes, approve for 12 months b. If no, clinical review required

Note:

Medication step therapy guidelines are used as a basis for making coverage decisions and do not serve as medical advice. Coverage of medications is subject to plan provisions. Additional coverage restrictions not listed in the guidelines may apply.



Antiglaucoma Agents Step Therapy Guidelines

Affected Medication(s)

- Alphagan P (brimonidine tartrate) 0.1% drops
- Alphagan P (brimonidine tartrate) 0.15% eye drops
- Apraclonidine 0.5% eye drops
- Azopt (brinzolamide) ophthalmic drops
- Betimol (timolol) eye drops
- Betoptic S (betaxolol hydrochloride) 0.25% eye drops
- Bimatoprost eye drops
- Brimonidine tartrate 0.1% drops
- Brimonidine tartrate 0.15% drops
- Brinzolamide ophthalmic drops
- Iopidine 1% (apraclonidine) eye drops
- Istalol 0.5% (timolol 0.5%) eye drops
- Lumigan (bimatoprost) ophthalmic drops
- Rhopressa (netarsudil mesylate) ophthalmic drops
- Simbrinza (brinzolamide/ brimonidine tartrate) eye drop
- Timolol 0.5% eye drops (Istalol generic)
- Timolol maleate 0.25% and 0.5% eye drops (Timoptic Ocudose generic)
- Timoptic (rimolol maleate) 0.25 and 0.5% Ocudose drops
- Vyzulta (latanoprostene bunod) ophthalmic drops

Step Therapy Requirements

Step 1 Drug(s):

- Brimonidine 0.2% drops
- Carteolol drops
- Dorzolamide drops
- Latanoprost drops
- Levobunolol drops
- Timolol maleate drops (Timoptic generic)

Step Therapy Criteria

1. Prescription claim for TWO Step 1 Drug(s) within the past 180 days (Note: 90 days of claims history required for authorization)
 - a. If yes, approve for 12 months
 - b. If no, continue to #2
2. If no claim history of Step 1 Drug(s), documentation of trial, intolerance or contraindication to TWO Step 1 Drugs is required
 - a. If yes, approve for 12 months
 - b. If no, clinical review required

Note:

Last Reviewed: 10/3/18, 3/20/19, 9/16/20, 11/17/21, 3/17/23, 11/20/23, 9/20/24, 11/15/24, 11/21/25

Effective Date: 1/1/19, 5/1/19, 11/15/20, 1/1/22, 6/1/23, 2/1/24, 10/15/24, 1/1/25, 1/1/26



Medication step therapy guidelines are used as a basis for making coverage decisions and do not serve as medical advice. Coverage of medications is subject to plan provisions. Additional coverage restrictions not listed in the guidelines may apply.

Last Reviewed: 10/3/18, 3/20/19, 9/16/20, 11/17/21, 3/17/23, 11/20/23, 9/20/24, 11/15/24, 11/21/25

Effective Date: 1/1/19, 5/1/19, 11/15/20, 1/1/22, 6/1/23, 2/1/24, 10/15/24, 1/1/25, 1/1/26



Antihypertensive Agents Step Therapy Guidelines

Affected Medication(s)

- Aliskiren hemifumarate
- Amlodipine besylate-valsartan-hydrochlorothiazide oral tablet
- Atacand (candesartan cilexetil) oral tablet
- Atacand HCT (candesartan cilexetil-hydrochlorothiazide) oral tablet
- Candesartan cilexetil oral tablet
- Candesartan cilexetil-hydrochlorothiazide oral tablet
- Captopril-hydrochlorothiazide oral tablet
- Edarbi (azilsartan medoxomil) oral tablet
- Azilsartan medoxomil oral tablet
- Edarbyclor (azilsartan medoxomil-chlorthalidone) oral tablet
- Exforge HCT (amlodipine besylate-valsartan-hydrochlorothiazide) oral tablet
- Micardis HCT (telmisartan-hydrochlorothiazide) oral tablet
- Olmesartan-amlodipine-hydrochlorothiazide oral tablet
- Prestalia (perindopril arginine-amlodipine besylate) oral tablet
- Tekturna (aliskiren hemifumarate) oral tablet
- Telmisartan-amlodipine besylate oral tablet
- Telmisartan-hydrochlorothiazide oral tablet
- Trandolapril-verapamil oral tablet
- Tribenzor (olmesartan medoxomil-amlodipine besylate-hydrochlorothiazide) oral tablet
- Widaplik (telmisartan-amlodipine-indapamide) oral tablet

Step Therapy Requirements

Step 1 Drug(s):

- Bisoprolol-hydrochlorothiazide oral tablet
- Irbesartan oral tablet
- Irbesartan-hydrochlorothiazide oral tablet
- Losartan potassium oral tablet
- Losartan-hydrochlorothiazide oral tablet
- Olmesartan-hydrochlorothiazide oral tablet
- Valsartan oral tablet
- Valsartan-hydrochlorothiazide oral tablet

Step Therapy Criteria

1. Prescription claim for TWO Step 1 Drug(s) within the past 180 days (Note: 90 days of claims history required for authorization)
 - a. If yes, approve for 12 months
 - b. If no, continue to #2
2. If no claim history of Step 1 Drug(s), documentation of trial, intolerance or contraindication to TWO Step 1 Drug is required
 - a. If yes, approve for 12 months



b. If no, clinical review required

Note:

Medication step therapy guidelines are used as a basis for making coverage decisions and do not serve as medical advice. Coverage of medications is subject to plan provisions. Additional coverage restrictions not listed in the guidelines may apply.



Antiparkinson Agents Step Therapy Guidelines

Affected Medication(s)
• Neupro transdermal patch • Ongentys oral capsule • Xadago oral tablet
Step Therapy Requirements
Step 1 Drug(s): • Entacapone • Pramipexole • Ropinirole • Selegiline capsule or tablet
Step Therapy Criteria
1. Prescription claim for TWO Step 1 Drug(s) within the past 180 days (Note: 90 days of claims history required for authorization) a. If yes, approve for 12 months b. If no, continue to #2 2. If no claim history of TWO Step 1 Drug(s), documentation of trial, intolerance or contraindication to TWO Step 1 Drug(s) is required a. If yes, approve for 12 months b. If no, clinical review required

Note:

Medication step therapy guidelines are used as a basis for making coverage decisions and do not serve as medical advice. Coverage of medications is subject to plan provisions. Additional coverage restrictions not listed in the guidelines may apply.



Aptiom® (eslicarbazepine), Xcopri® (cenobamate) Step Therapy Guidelines

Affected Medication(s)
• Aptiom (eslicarbazepine) oral tablet • Eslicarbazepine oral tablet • Xcopri (cenobamate) oral tablet
Step Therapy Requirements
Step 1 Drug(s): • Carbamazepine oral tablet • Gabapentin oral capsule • Gabapentin oral tablet • Lacosamide oral tablet • Oxcarbazepine oral tablet • Phenobarbital oral tablet • Phenytoin oral capsule • Pregabalin oral capsule • Primidone oral tablet
Step Therapy Criteria
1. Prescription claim for TWO Step 1 Drugs within the past 180 days (Note: 90 days of claims history required for authorization) a. If yes, approve for 12 months b. If no, continue to #2 2. If no claim history of Step 1 Drugs, documentation of trial, intolerance or contraindication to TWO Step 1 Drugs are required a. If yes, approve for 12 months b. If no, clinical review required

Note:

Medication step therapy guidelines are used as a basis for making coverage decisions and do not serve as medical advice. Coverage of medications is subject to plan provisions. Additional coverage restrictions not listed in the guidelines may apply.



Armour Thyroid Step Therapy Guidelines

Affected Medication(s)	
Armour Thyroid oral tablet	
Step Therapy Requirements	
Step 1 Drug(s): - Levothyroxine tablet - Liothyronine tablet	
Step Therapy Criteria	
- Prescription claim for TWO Step 1 Drug within the past 180 days (Note: 90 days of claims history required for authorization) - If yes, approve for 12 months - If no, continue to #2 - If no claim history of Step 1 Drug, documentation of trial, intolerance or contraindication to TWO Step 1 Drug is required - If yes, approve for 12 months - If no, clinical review required	

Note:

Medication step therapy guidelines are used as a basis for making coverage decisions and do not serve as medical advice. Coverage of medications is subject to plan provisions. Additional coverage restrictions not listed in the guidelines may apply.



Atypical Antipsychotic Agents Step Therapy Guidelines

Affected Medication(s)	
Step 2 Drug(s) • Invega (paliperidone) ER oral tablet • Lybalvi (olanzapine-samidorphan) oral tablet • Paliperidone ER oral tablet • Rexulti (brexpiprazole) oral tablet • Saphris (asenapine maleate) sublingual tablet • Asenapine sublingual tablet • Vraylar (cariprazine) oral capsule Step 3 Drug(s) • Caplyta (lumateperone) oral capsule • Fanapt (iloperidone) oral tablet • Secuado (asenapine) transdermal	
Step Therapy Requirements	
Step 1 Drug(s) • Olanzapine oral tablet • Risperidone oral tablet Step 2 Drug(s) • Invega (paliperidone) ER oral tablet • Lybalvi (olanzapine-samidorphan) oral tablet • Paliperidone ER oral tablet • Rexulti (brexpiprazole) oral tablet • Saphris (asenapine maleate) sublingual tablet • Asenapine sublingual tablet • Vraylar (cariprazine) oral capsule	
Step Therapy Criteria	
1. Prescription claim for ONE Step 1 Drug(s) within the past 180 days (Note: 90 days of claims history required for authorization) a. If yes for Step 2 drug, approve for 12 months b. If yes for Step 3 drug, continue to #3 c. If no for Step 2 or Step 3 drug, continue to #2 2. If no claim history of Step 1 Drug(s), documentation of trial, intolerance or contraindication to ONE Step 1 Drug is required a. If yes for Step 2 drug, approve for 12 months b. If yes for Step 3 drug, continue to #3 c. If no for Step 2 or Step 3 drug, clinical review required	



3. Prescription claim for ONE Step 2 Drug(s) within the past 180 days (Note: 90 days of claim history required for authorization)
 - a. If yes, approve for 12 months
 - b. If no, continue to #4
4. If no claim history of Step 2 Drug(s), documentation of trial, intolerance or contraindication to ONE Step 2 Drugs required.
 - a. If yes, approve for 12 months
 - b. If no, clinical review required

Note:

Medication step therapy guidelines are used as a basis for making coverage decisions and do not serve as medical advice. Coverage of medications is subject to plan provisions. Additional coverage restrictions not listed in the guidelines may apply.



Bisphosphonate Agents Step Therapy Guidelines

Affected Medication(s)	
• Actonel (risedronate sodium) oral tablet • Atelvia (risedronate sodium) DR oral tablet • Binosto (alendronate sodium) effervescent tablet • Fosamax Plus D (alendronate sodium-cholecalciferol) oral tablet • Risedronate sodium DR oral tablet • Risedronate sodium oral tablet	
Step Therapy Requirements	
Step 1 Drug(s): • Alendronate sodium oral tablet	
Step Therapy Criteria	
1. Prescription claim for ONE Step 1 Drug(s) within the past 180 days (Note: 90 days of claims history required for authorization) a. If yes, approve for 12 months b. If no, continue to #2 2. If no claim history of Step 1 Drug(s), documentation of trial, intolerance or contraindication to ONE Step 1 Drug is required a. If yes, approve for 12 months b. If no, clinical review required	

Note:

Medication step therapy guidelines are used as a basis for making coverage decisions and do not serve as medical advice. Coverage of medications is subject to plan provisions. Additional coverage restrictions not listed in the guidelines may apply.



Constipation Agents Step Therapy Guidelines

Affected Medication(s)

Step 2 Drug(s)

- Linzess (linaclotide) oral capsule
- Motegrity (prucalopride) oral tablet
- Prucalopride oral tablet
- Movantik (naloxegol) oral tablet
- Symproic (naldemedine) oral tablet

Step 3 Drug(s)

- Amitiza (lubiprostone) oral capsule
- Lubiprostone oral capsule
- Trulance (plecanatide) oral tablet

Step Therapy Requirements

Step 1 Drug(s):

- Polyethylene glycol 3350 powder
- Lactulose solution

Step 2 Drug(s)

- Linzess (linaclotide) oral capsule
- Motegrity (prucalopride) oral tablet
- Prucalopride oral tablet
- Movantik (naloxegol) oral tablet
- Symproic (naldemedine) oral tablet

Step Therapy Criteria

1. Prescription claim for ONE Step 1 Drug(s) within the past 180 days (Note: 90 days of claims history required for authorization)
 - a. If yes for Step 2 drug, approve for 12 months
 - b. If yes for Step 3 drug, continue to #3
 - c. If no for Step 2 or Step 3 drug, continue to #2
2. If no claim history of Step 1 Drug(s), documentation of trial, intolerance or contraindication to ONE Step 1 Drug is required
 - a. If yes for Step 2 drug, approve for 12 months
 - b. If yes for Step 3 drug, continue to #3
 - c. If no for Step 2 or Step 3 drug, clinical review required
3. Prescription claim for ONE Step 2 Drug(s) within the past 180 days (Note: 90 days of claim history required for authorization)
 - a. If yes, approve for 12 months



b. If no, continue to #4

4. If no claim history of Step 2 Drug(s), documentation of trial, intolerance or contraindication to ONE Step 2 Drugs required.

a. If yes, approve for 12 months

b. If no, clinical review required

Note:

Medication step therapy guidelines are used as a basis for making coverage decisions and do not serve as medical advice. Coverage of medications is subject to plan provisions. Additional coverage restrictions not listed in the guidelines may apply.



Coreg CR® (carvedilol phosphate) Step Therapy Guidelines

Affected Medication(s)	
• Carvedilol ER (carvedilol phosphate) oral capsule • Coreg CR (carvedilol phosphate) oral capsule	
Step Therapy Requirements	
Step 1 Drug(s): • Bisoprolol oral tablet • Carvedilol oral tablet • Metoprolol succinate ER oral tablet • Nebivolol oral tablet	
Step Therapy Criteria	
1. Prescription claim for TWO Step 1 Drugs within the past 180 days (Note: 90 days of claims history required for authorization) a. If yes, approve for 12 months b. If no, continue to #2 2. If no claim history of Step 1 Drugs, documentation of trial, intolerance or contraindication to TWO Step 1 Drugs is required a. If yes, approve for 12 months b. If no, clinical review required	

Note:

Medication step therapy guidelines are used as a basis for making coverage decisions and do not serve as medical advice. Coverage of medications is subject to plan provisions. Additional coverage restrictions not listed in the guidelines may apply.



Dipeptidyl Peptidase-4 Enzyme Inhibitor Agents Step Therapy Guidelines

Affected Medication(s)

Step 2 Drug(s):

- Januvia (sitagliptin phosphate) oral tablet
- Janumet (sitagliptin phosphate-metformin HCl) oral tablet
- Janumet XR (sitagliptin phosphate-metformin HCl) oral tablet
- Jentadueto (linagliptin-metformin HCl) oral tablet
- Jentadueto XR (linagliptin-metformin HCl) oral tablet
- Linagliptin oral tablet
- Linagliptin-metformin HCl oral tablet
- Sitagliptin phosphate-metformin oral tablet
- Sitagliptin phosphate-metformin ER oral tablet
- Tradjenta (linagliptin) oral tablet

Step 3 Drug(s)

- Alogliptin benzoate oral tablet
- Alogliptin benzoate-pioglitazone HCl oral tablet
- Kazano (alogliptin benzoate-metformin HCl) oral tablet
- Alogliptin benzoate-metformin HCl oral tablet
- Kombiglyze XR (saxagliptin HCl-metformin HCl) oral tablet
- Onglyza (saxagliptin HCl) oral tablet
- Oseni (alogliptin benzoate-pioglitazone HCl) oral tablet
- Nesina (alogliptin) oral tablet
- Saxagliptin-metformin HCl ER oral tablet
- Sitagliptin oral tablet
- Sitagliptin-metformin oral tablet
- Zituvi met (sitagliptin-metformin) oral tablet
- Zituvi met XR (sitagliptin-metformin) oral tablet
- Zituvio (sitagliptin) oral tablet

Step Therapy Requirements

Step 1 Drug(s):

- Metformin HCl oral tablet
- Metformin HCl ER oral tablet

Step 2 Drug(s):

- Januvia (sitagliptin phosphate) oral tablet
- Janumet (sitagliptin phosphate-metformin HCl) oral tablet
- Janumet XR (sitagliptin phosphate-metformin HCl) oral tablet
- Jentadueto (linagliptin-metformin HCl) oral tablet
- Jentadueto XR (linagliptin-metformin HCl) oral tablet
- Linagliptin oral tablet
- Linagliptin-metformin HCl oral tablet



- Tradjenta (linagliptin) oral tablet

Step Therapy Criteria

1. Is the request for a Step 2 medication?
 - a. If yes continue to #2
 - b. If no, continue to #4
2. Does the member have prescription claim for ONE Step 1 Drug within the past 180 days? (Note: 90 days of claims history required for authorization)
 - a. If yes, approve Step 2 Drug for 12 months
 - b. If no, continue to #3
3. Does the member have documentation of trial, intolerance or contraindication to ONE Step 1 Drug?
 - a. If yes, approve Step 2 Drug for 12 months.
 - b. If no, clinical review required
4. Does the member have prescription claim for ONE Step 1 Drug within the past 180 days? (Note: 90 days of claims history required for authorization)
 - a. If yes, continue to #6
 - b. If no, continue to #5
5. Does the member have documentation of trial, intolerance or contraindication to ONE Step 1 Drug?
 - a. If yes, continue to #6
 - b. If no, clinical review required
6. Does the member have prescription claim(s) for TWO Step 2 Drugs containing different DPP4 inhibitors within the past 180 days? (Note: 90 days of claims history required for authorization)
 - a. If yes, approve Step 3 drug for 12 months
 - b. If no, continue to #7
7. Does the member have documentation of trial, intolerance, or contraindication to TWO Step 2 Drugs contain different DPP4 inhibitors?
 - a. If yes, approve Step 3 drug for 12 months
 - b. If no, clinical review is required

Note:

Medication step therapy guidelines are used as a basis for making coverage decisions and do not serve as medical advice. Coverage of medications is subject to plan provisions. Additional coverage restrictions not listed in the guidelines may apply.

Last Reviewed: 10/3, 3/17/21, 3/16/22, 3/17/23, 9/15/23, 1/19/24, 5/17/24, 7/19/24, 11/15/24, 11/21/25, 1/16/26, 3/20/26, 9/18/26
Effective Date: 1/1/19, 5/1/21, 5/1/22, 11/20/23, 3/1/24, 6/15/24, 8/15/24, 1/1/25, 4/8/26, 10/1/26



Dry Eye Agents Step Therapy Guidelines

Affected Medication(s)	
• Tyrvaya (varenicline) Nasal Spray • Xiidra (lifitegrast) Ophthalmic Solution	
Step Therapy Requirements	
Step 1 Drug(s): • Artificial tears • Cyclosporine Ophthalmic Solution	
Step Therapy Criteria	
1. Prescription claim for TWO Step 1 Drugs within the past 180 days (Note: 90 days of claims history required for authorization) a. If yes, approve for 12 months b. If no, continue to #2 2. If no claim history of Step 1 Drugs, documentation of trial, intolerance or contraindication to TWO Step 1 Drugs is required a. If yes, approve for 12 months b. If no, clinical review required	

Note:

Medication step therapy guidelines are used as a basis for making coverage decisions and do not serve as medical advice. Coverage of medications is subject to plan provisions. Additional coverage restrictions not listed in the guidelines may apply.



fidaxomicin Step Therapy Guidelines

Affected Medication(s)

- Difacid (fidaxomicin) oral tablet
- Difacid (fidaxomicin) oral suspension
- fidaxomicin oral tablet

Step Therapy Requirements

Step 1 Drug(s):

- Vancomycin HCl

Step Therapy Criteria

1. Prescription claim for ONE Step 1 Drug within the past 180 days
 - a. If yes, approve for 12 months
 - b. If no, continue to #2
2. If no claim history of Step 1 Drug, documentation of trial, intolerance or contraindication to ONE Step 1 Drugs is required
 - a. If yes, approve for 12 months
 - b. If no, clinical review required

Note:

Medication step therapy guidelines are used as a basis for making coverage decisions and do not serve as medical advice. Coverage of medications is subject to plan provisions. Additional coverage restrictions not listed in the guidelines may apply.



Inhaled Corticosteroid- Long Acting Beta Agonist Combination Agents Step Therapy Guidelines

Affected Medication(s)
• Advair HFA (fluticasone propionate-salmeterol xinafoate) inhalation aerosol • Dulera (mometasone furoate-formoterol fumarate) inhalation aerosol • Fluticasone propionate-salmeterol xinafoate inhalation aerosol
Step Therapy Requirements
Step 1 Drug(s): • Fluticasone propionate-salmeterol inhalation powder • Breo Ellipta (fluticasone furoate-vilanterol) inhalation powder • Fluticasone furoate-vilanterol inhalation powder • Symbicort (budesonide-formoterol fumarate) inhaler • Breyna (budesonide-formoterol fumarate) inhaler • Budesonide-formoterol fumarate inhaler
Step Therapy Criteria
1. Prescription claim for TWO Step 1 Drugs within the past 180 days (Note: 90 days of claims history required for authorization) a. If yes, approve for 12 months b. If no, continue to #2 2. If no claim history of Step 1 Drugs, documentation of trial, intolerance or contraindication to TWO Step 1 Drugs is required a. If yes, approve for 12 months b. If no, clinical review required

Note:

Medication step therapy guidelines are used as a basis for making coverage decisions and do not serve as medical advice. Coverage of medications is subject to plan provisions. Additional coverage restrictions not listed in the guidelines may apply.



Inhaled Corticosteroid Agents Step Therapy Guidelines

Affected Medication(s)
• Asmanex HFA • Asmanex Twisthaler • Alvesco Inhaler • Beclomethasone Inhaler • Pulmicort Flexhaler • Qvar Redihaler
Step Therapy Requirements
Step 1 Drug(s): • Arnuity Ellipta • Fluticasone propionate HFA • Fluticasone propionate diskus
Step Therapy Criteria
1. Prescription claim for ONE Step 1 Drugs within the past 180 days (Note: 90 days of claims history required for authorization) a. If yes, approve for 12 months b. If no, continue to #2 2. If no claim history of Step 1 Drugs, documentation of trial, intolerance or contraindication to TWO Step 1 Drugs is required a. If yes, approve for 12 months b. If no, clinical review required

Note:

Medication step therapy guidelines are used as a basis for making coverage decisions and do not serve as medical advice. Coverage of medications is subject to plan provisions. Additional coverage restrictions not listed in the guidelines may apply.



Insomnia Agents Step Therapy Guidelines

Affected Medication(s)

- Dayvigo (lemborexant) oral tablet
- Doxepin oral tablet
- Edluar (zolpidem tartrate) sublingual tablet
- Silenor (doxepin HCl) oral tablet
- Zolpidem tartrate sublingual tablet
- Zolpidem tartrate oral capsule

Step Therapy Requirements

Step 1 Drug(s):

- Estazolam oral tablet
- Eszopiclone oral tablet
- Ramelteon oral tablet
- Temazepam oral capsule
- Zaleplon oral capsule
- Zolpidem tartrate oral tablet

Step Therapy Criteria

1. Prescription claim for TWO Step 1 Drug(s) within the past 180 days (Note: 90 days of claims history required for authorization)
 - a. If yes, approve for 12 months
 - b. If no, continue to #2
2. If no claim history of Step 1 Drug(s), documentation of trial, intolerance or contraindication to TWO Step 1 Drug is required
 - a. If yes, approve for 12 months
 - b. If no, clinical review required

Note:

Medication step therapy guidelines are used as a basis for making coverage decisions and do not serve as medical advice. Coverage of medications is subject to plan provisions. Additional coverage restrictions not listed in the guidelines may apply.



Long-Acting Beta Agonist & Long Acting Antimuscarinic Combination Agents Step Therapy Guidelines

Affected Medication(s)	
• Bevespi Aerosphere • Duaklir Pressair	
Step Therapy Requirements	
Step 1 Drug(s): • Anoro Ellipta • Stiolto Respimat • Umeclidinium-Vilanterol Inhalation Powder	
Step Therapy Criteria	
1. Prescription claim for ONE Step 1 Drug(s) within the past 180 days (Note: 90 days of claims history required for authorization) a. If yes, approve for 12 months b. If no, continue to #2 2. If no claim history of Step 1 Drug(s), documentation of trial, intolerance or contraindication to ONE Step 1 Drug is required a. If yes, approve for 12 months b. If no, clinical review required	

Note:

Medication step therapy guidelines are used as a basis for making coverage decisions and do not serve as medical advice. Coverage of medications is subject to plan provisions. Additional coverage restrictions not listed in the guidelines may apply.



Long-Acting Beta Agonist Agents Step Therapy Guidelines

Affected Medication(s)	
• arformoterol tartrate inhalation solution • Perforomist (fomoterol fumerate) inhalation solution • formoterol fumarate inhalation solution	
Step Therapy Requirements	
Step 1 Drug(s): • Serevent Diskus (salmeterol xinafoate) inhalation powder • Striverdi Respimat (olodaterol) inhaler spray	
Step Therapy Criteria	
1. Prescription claim for ONE Step 1 Drug within the past 180 days (Note: 90 days of claims history required for authorization) a. If yes, approve for 12 months b. If no, continue to #2 2. If no claim history of Step 1 Drug, documentation of trial, intolerance or contraindication to ONE Step 1 Drug is required a. If yes, approve for 12 months b. If no, clinical review required	

Note:

Medication step therapy guidelines are used as a basis for making coverage decisions and do not serve as medical advice. Coverage of medications is subject to plan provisions. Additional coverage restrictions not listed in the guidelines may apply.



Long-Acting Antimuscarinic Agents Step Therapy Guidelines

6/1/Affected Medication(s)
- Tudorza Pressair (aclidinium bromide) inhalation powder - Umeclidinium Ellipta inhalation powder - Yupelri (revefenacin) solution
Step Therapy Requirements
Step 1 Drug(s): - Incruse Ellipta (umeclidinium bromide) inhalation powder - Spiriva (tiotropium bromide) Handihaler/Respimat - tiotropium bromide inhalation powder capsules
Step Therapy Criteria
- Prescription claim for TWO Step 1 Drug(s) within the past 180 days (Note: 90 days of claims history required for authorization) - If yes, approve for 12 months - If no, continue to #2 - If no claim history of Step 1 Drug(s), documentation of trial, intolerance or contraindication to TWO Step 1 Drug is required - If yes, approve for 12 months - If no, clinical review required

Note:

Medication step therapy guidelines are used as a basis for making coverage decisions and do not serve as medical advice. Coverage of medications is subject to plan provisions. Additional coverage restrictions not listed in the guidelines may apply.



Long-Acting Insulin Agents Step Therapy Guidelines

Affected Medication(s)
• Awiqli Flextouch (insulin icodec-abae) subcutaneous insulin pen • Basaglar Kwikpen U-100 (insulin glargine) subcutaneous insulin pen • Basaglar Tempo U-100 (insulin glargine) subcutaneous insulin pen • Semglee YFGN (insulin glargine-yfgn) subcutaneous vial • Semglee YFGN (insulin glargine-yfgn) subcutaneous pen • Toujeo Max Solostar (insulin glargine) subcutaneous insulin pen • Toujeo Solostar (insulin glargine) subcutaneous insulin pen • Insulin glargine 100 unit/mL subcutaneous vial
Step Therapy Requirements
Step 1 Drug(s): • Insulin glargine-yfgn subcutaneous vial • Insulin glargine-yfgn subcutaneous pen • Insulin glargine U-300 Max Solostar subcutaneous insulin pen • Insulin glargine U-300 Solostar subcutaneous insulin pen • Rezvoglar (insulin glargine-aglr) subcutaneous kwikpen • Lantus subcutaneous vial • Lantus Solostar subcutaneous pen
Step Therapy Criteria
1. Prescription claim for ONE Step 1 Drug(s) within the past 180 days (Note: 90 days of claims history required for authorization) a. If yes, approve for 12 months b. If no, continue to #2 2. If no claim history of Step 1 Drug(s), documentation of trial, intolerance or contraindication to ONE Step 1 Drug is required a. If yes, approve for 12 months b. If no, clinical review required

Note:

Medication step therapy guidelines are used as a basis for making coverage decisions and do not serve as medical advice. Coverage of medications is subject to plan provisions. Additional coverage restrictions not listed in the guidelines may apply.



Long-Acting Opioid Agents Step Therapy Guidelines

Affected Medication(s)
- Hydromorphone ER oral tablet - Morphine sulfate ER oral capsule - Nucynta ER - Oxymorphone ER oral tablet - Oxycontin (oxycodone HCl) oral tablet - Tapentadol ER - Xtampza ER (oxycodone myristate) oral capsule
Step Therapy Requirements
Step 1 Drug(s): - Fentanyl transdermal patch - Morphine sulfate ER oral tablet
Step Therapy Criteria
- Prescription claim for ONE Step 1 Drug within the past 180 days (Note: 90 days of claims history required for authorization) - If yes, approve for 12 months - If no, continue to #2 - If no claim history of Step 1 Drug(s), documentation of trial, intolerance or contraindication to ONE Step 1 Drug is required - If yes, approve for 12 months - If no, clinical review required

Note:

Medication step therapy guidelines are used as a basis for making coverage decisions and do not serve as medical advice. Coverage of medications is subject to plan provisions. Additional coverage restrictions not listed in the guidelines may apply.



Nasal Steroid Agents Step Therapy Guidelines

Affected Medication(s)	
• Dymista (azelastine HCl-fluticasone propionate) nasal spray • Azelastine-fluticasone nasal spray • Ryaltris (olopatadine-mometasone) spray	
Step Therapy Requirements	
Step 1 Drug(s): • Flunisolide nasal spray • Fluticasone propionate nasal spray • Olopatadine nasal spray	
Step Therapy Criteria	
1. Prescription claim for ONE Step 1 Drug(s) within the past 180 days (Note: 90 days of claims history required for authorization) a. If yes, approve for 12 months b. If no, continue to #2 2. If no claim history of Step 1 Drug(s), documentation of trial, intolerance or contraindication to ONE Step 1 Drugs is required a. If yes, approve for 12 months b. If no, clinical review required	

Note:

Medication step therapy guidelines are used as a basis for making coverage decisions and do not serve as medical advice. Coverage of medications is subject to plan provisions. Additional coverage restrictions not listed in the guidelines may apply.



Nexletol Step Therapy Guidelines

Affected Medication(s)	
Nexletol (bempedoic acid) tablet	
Step Therapy Requirements	
Step 1 Drug(s): - Atorvastatin calcium oral tablet - Ezetimibe oral tablet - Lovastatin oral tablet - Pravastatin sodium oral tablet - Rosuvastatin calcium oral tablet - Simvastatin oral tablet	
Step Therapy Criteria	
- Prescription claim for TWO Step 1 Drug(s) within the past 180 days (Note: 90 days of claims history required for authorization) - If yes, approve for 12 months - If no, continue to #2 - If no claim history of Step 1 Drug(s), documentation of trial, intolerance or contraindication to TWO Step 1 Drugs is required - If yes, approve for 12 months - If no, clinical review required	

Note:

Medication step therapy guidelines are used as a basis for making coverage decisions and do not serve as medical advice. Coverage of medications is subject to plan provisions. Additional coverage restrictions not listed in the guidelines may apply.



NSAID Agents Step Therapy Guidelines

Affected Medication(s)
• Daypro oral tablet • Ketoprofen oral capsule • Ketoprofen ER oral capsule • Kiprofen oral capsule • Meclofenamate oral capsule • Orudis (ketoprofen) capsule • Oxaprozin oral tablet • Sprix (ketorolac tromethamine) nasal spray • Ketorolac tromethamine nasal spray
Step Therapy Requirements
Step 1 Drug(s): • Diclofenac potassium oral tablet • Diclofenac sodium DR oral tablet • Diclofenac sodium ER oral tablet • Ibuprofen oral tablet • Indomethacin oral capsule • Meloxicam oral tablet • Nabumetone oral tablet • Naproxen oral tablet • Naproxen DR oral tablet • Piroxicam oral capsule • Sulindac oral tablet
Step Therapy Criteria
1. Prescription claim for TWO Step 1 Drug(s) within the past 180 days (Note: 90 days of claims history required for authorization) a. If yes, approve for 12 months b. If no, continue to #2 2. If no claim history of Step 1 Drug(s), documentation of trial, intolerance or contraindication to TWO Step 1 Drugs is required a. If yes, approve for 12 months b. If no, clinical review required

Note:

Medication step therapy guidelines are used as a basis for making coverage decisions and do not serve as medical advice. Coverage of medications is subject to plan provisions. Additional coverage restrictions not listed in the guidelines may apply.



Overactive Bladder Agents Step Therapy Guidelines

Affected Medication(s)
• Darifenacin ER oral tablet • fesoterodine fumarate ER oral tablet • Gemtesa (vibegron) oral tablet • Mirabegron ER oral tablet • Mirabegron ER oral suspension • Myrbetriq (mirabegron) ER suspension • Myrbetriq (mirabegron) ER oral tablet • Oxytrol (oxybutynin) transdermal patch • Toviaz (fesoterodine fumarate) ER oral tablet • Trospium ER oral capsule • Vesicare LS (solifenacin succinate) oral suspension
Step Therapy Requirements
Step 1 Drug(s): • Oxybutynin chloride oral tablet • Oxybutynin chloride ER oral tablet • Tolterodine tartrate oral tablet • Trospium chloride oral tablet • Solifenacin succinate oral tablet
Step Therapy Criteria
1. Prescription claim for TWO Step 1 Drug(s) within the past 180 days (Note: 90 days of claims history required for authorization) a. If yes, approve for 12 months b. If no, continue to #2 2. If no claim history of Step 1 Drug(s), documentation of trial, intolerance or contraindication to TWO Step 1 Drugs is required a. If yes, approve for 12 months b. If no, clinical review required

Note:

Medication step therapy guidelines are used as a basis for making coverage decisions and do not serve as medical advice. Coverage of medications is subject to plan provisions. Additional coverage restrictions not listed in the guidelines may apply.



Pancreatic Enzymes Step Therapy Guidelines

Affected Medication(s)

- Pancreaze (lipase/protease/amylase) capsule
- Pertzye (lipase/protease/amylase) capsule
- Viokace (lipase/protease/amylase) capsule

Step Therapy Requirements

Step 1 Drug(s):

- Creon (lipase/protease/amylase) capsule
- Zenpep (lipase/protease/amylase) capsule

Step Therapy Criteria

1. Prescription claim for TWO Step 1 Drug(s) within the past 180 days (Note: 90 days of claims history required for authorization)
 - a. If yes, approve for 12 months
 - b. If no, continue to #2
2. If no claim history of Step 1 Drug(s), documentation of trial, intolerance or contraindication to TWO Step 1 Drug is required
 - a. If yes, approve for 12 months
 - b. If no, clinical review required



PCSK9 Inhibitor Agents Step Therapy Guidelines

Affected Medication(s)	
• Lerochol subcutaneous solution • Praluent subcutaneous solution • Repatha subcutaneous solution	
Step Therapy Requirements	
Step 1 Drug(s): • Atorvastatin calcium oral tablet • Lovastatin oral tablet • Pravastatin sodium oral tablet • Rosuvastatin calcium oral tablet • Simvastatin oral tablet	
Step Therapy Criteria	
1. Prescription claim for ONE Step 1 Drug(s) within the past 180 days (Note: 84 days of claims history required for authorization) a. If yes, approve for 12 months b. If no, continue to #2 2. If no claim history of Step 1 Drug(s), documentation of trial, intolerance or contraindication to ONE Step 1 Drugs is required a. If yes, approve for 12 months b. If no, clinical review required	

Note:

Medication step therapy guidelines are used as a basis for making coverage decisions and do not serve as medical advice. Coverage of medications is subject to plan provisions. Additional coverage restrictions not listed in the guidelines may apply.



Proton Pump Inhibitor Agents Step Therapy Guidelines

Affected Medication(s)

- Aciphex Sprinkle (rabeprazole sodium) DR oral capsule
- rabeprazole sprinkle DR oral capsule
- Dexilant (dexlansoprazole) DR oral capsule
- dexlansoprazole DR oral capsule
- Nexium (esomeprazole magnesium) DR oral suspension packet
- esomeprazole DR oral suspension packet
- esomeprazole magnesium suspension packet
- Prevacid (lansoprazole) DR Solutab
- lansoprazole ODT tablet
- Prilosec (omeprazole magnesium) DR oral suspension packet
- Protonix (pantoprazole sodium) DR oral granule packet
- pantoprazole DR oral granule packet

Step Therapy Requirements

Step 1 Drug(s):

- esomeprazole DR oral capsule
- lansoprazole DR oral capsule
- omeprazole DR oral capsule
- pantoprazole sodium DR oral tablet
- rabeprazole DR oral tablet

Step Therapy Criteria

1. Prescription claim for ONE Step 1 Drug(s) within the past 180 days (Note: 90 days of claims history required for authorization)
 - a. If yes, approve for 12 months
 - b. If no, continue to #2
2. If no claim history of Step 1 Drug(s), documentation of trial, intolerance or contraindication to ONE Step 1 Drug is required
 - a. If yes, approve for 12 months
 - b. If no, clinical review required

Note:

Medication step therapy guidelines are used as a basis for making coverage decisions and do not serve as medical advice. Coverage of medications is subject to plan provisions. Additional coverage restrictions not listed in the guidelines may apply.



Pregabalin CR Step Therapy Guidelines

Affected Medication(s)	
• Lyrica CR (pregabalin) oral tablet • Pregabalin CR tablet	
Step Therapy Requirements	
Step 1 Drug(s): • Duloxetine HCl DR oral capsule • Gabapentin oral capsule • Gabapentin oral solution • Gabapentin oral tablet	
Step Therapy Criteria	
1. Prescription claim for TWO Step 1 Drug(s) within the past 180 days (Note: 90 days of claims history required for authorization) a. If yes, approve for 12 months b. If no, continue to #2 2. If no claim history of Step 1 Drug(s), documentation of trial, intolerance or contraindication to TWO Step 1 Drugs is required a. If yes, approve for 12 months b. If no, clinical review required	

Note:

Medication step therapy guidelines are used as a basis for making coverage decisions and do not serve as medical advice. Coverage of medications is subject to plan provisions. Additional coverage restrictions not listed in the guidelines may apply.



Rosacea Agents Step Therapy Guidelines

Affected Medication(s)
• Finacea (azelaic acid) 15% foam • Metro lotion (metronidazole) 0.75% lotion • Metronidazole 0.75% lotion • Mirvaso (brimonidine tartrate) topical gel pump • Brimonidine tartrate topical gel pump • Rhofade (oxymetazoline HCl) topical cream • Oxymetazoline topical cream • Soolantra (ivermectin) 1% cream • Ivermectin 1% cream • Zilxi (minocycline) topical foam
Step Therapy Requirements
Step 1 Drug(s): • Metronidazole topical cream • Metronidazole topical gel pump • Metronidazole topical gel • Azelaic acid gel
Step Therapy Criteria
1. Prescription claim for TWO Step 1 Drug(s) within the past 180 days (Note: 90 days of claims history required for authorization) a. If yes, approve for 12 months b. If no, continue to #2 2. If no claim history of Step 1 Drug(s), documentation of trial, intolerance or contraindication to TWO Step 1 Drug is required a. If yes, approve for 12 months b. If no, clinical review required

Note:

Medication step therapy guidelines are used as a basis for making coverage decisions and do not serve as medical advice. Coverage of medications is subject to plan provisions. Additional coverage restrictions not listed in the guidelines may apply.



Sodium-Glucose Cotransporter-2 Inhibitors Step Therapy Guidelines

Affected Medication(s)

Step 2 Drugs:

- Bexagliflozin oral tablet
- Brenzavvy (bexagliflozin) oral tablet
- Dapagliflozin propanediol-saxagliptin HCl oral tablet
- Glyxambi (empagliflozin-linagliptin) oral tablet
- Inpefa (sotagliflozin) oral tablet
- Invokamet (canagliflozin-metformin HCl) oral tablet
- Invokamet XR (canagliflozin-metformin HCl) oral tablet
- Invokana (canagliflozin) oral tablet
- Qtern (dapagliflozin propanediol-saxagliptin HCl) oral tablet
- Segluromet (ertugliflozin pidolate-metformin HCl) oral tablet
- Steglatro (ertugliflozin pidolate) oral tablet
- Steglujan (ertugliflozin pidolate-sitagliptin phosphate) oral tablet

Step Therapy Requirements

Step 1 Drugs:

- Dapagliflozin propanediol oral tablet
- Dapagliflozin propanediol-metformin HCl ER oral tablet
- Jardiance (empagliflozin) oral tablet
- Synjardy (empagliflozin-metformin HCl) oral tablet
- Synjardy XR (empagliflozin-metformin HCl) oral tablet
- Trijardy XR (empagliflozin-linagliptin-metformin) oral tablet

Step Therapy Criteria

1. Does the member have prescription claim for TWO Step 1 Drug(s) within the past 180 days? (Note: 90 days of claims history required for authorization)
 - a. If yes, approve for 12 months
 - b. If no, continue to #2
2. Does the member have documentation of trial, intolerance or contraindication to TWO Step 1 Drug(s)?
 - a. If yes, approve for 12 months
 - b. If no, clinical review required

Note:

Medication step therapy guidelines are used as a basis for making coverage decisions and do not serve as medical advice. Coverage of medications is subject to plan provisions. Additional coverage restrictions not listed in the guidelines may apply.



Statin Agents Step Therapy Guidelines

Affected Medication(s)
• Ezallor Sprinkle (rosuvastatin) oral capsule • Fluvastatin sodium ER oral tablet • Fluvastatin sodium oral capsule • Lescol (fluvastatin) oral capsule • Lescol XL (fluvastatin) oral tablet • Livalo (pitavastatin calcium) oral tablet • Pitavastatin calcium oral tablet • Zypitomag (pitavastatin magnesium) oral tablet
Step Therapy Requirements
Step 1 Drug(s): • Atorvastatin calcium oral tablet • Lovastatin oral tablet • Pravastatin sodium oral tablet • Rosuvastatin calcium oral tablet • Simvastatin oral tablet
Step Therapy Criteria
1. Prescription claim for TWO Step 1 Drug(s) within the past 180 days (Note: 90 days of claims history required for authorization) a. If yes, approve for 12 months b. If no, continue to #2 2. If no claim history of Step 1 Drug(s), documentation of trial, intolerance or contraindication to TWO Step 1 Drugs is required a. If yes, approve for 12 months b. If no, clinical review required

Note:

Medication step therapy guidelines are used as a basis for making coverage decisions and do not serve as medical advice. Coverage of medications is subject to plan provisions. Additional coverage restrictions not listed in the guidelines may apply.



Tetracycline Antibiotic Agents Step Therapy Guidelines

Affected Medication(s)

- Doryx (doxycycline hyclate) DR oral tablet
- Doryx MPC (doxycycline hyclate) DR oral tablet
- Doxycycline 50mg oral tablet
- Doxycycline hyclate DR oral tablet (Doryx generic 50mg, 75mg, 80mg, 100mg, 150mg, 200mg)
- Doxycycline hyclate DR oral tablet (Targadox generic 50mg)
- Doxycycline hyclate 75 mg & 150 mg oral tablet (Acticlate generic)
- Doxycycline hyclate 75 mg oral capsule
- Doxycycline IR-DR oral capsule
- Emrosi (minocycline) ER oral capsule
- Minocycline HCl ER oral capsule
- Minocycline ER oral tablets
- Oracea (doxycycline monohydrate) oral capsule
- Solodyn ER (minocycline ER) oral tablet
- Targadox (doxycycline) oral tablet
- Ximino (minocycline HCl) ER oral capsule

Step Therapy Requirements

Step 1 Drug(s):

- Doxycycline monohydrate 50 mg, 75 mg, & 100 mg oral tablet
- Doxycycline monohydrate 50 mg & 100 mg oral capsule
- Minocycline HCl oral capsule
- Minocycline HCl oral tablet

Step Therapy Criteria

1. Prescription claim for ONE Step 1 Drug(s) within the past 180 days (Note: 90 days of claims history required for authorization)
 - a. If yes, approve for 12 months
 - b. If no, continue to #2
2. If no claim history of Step 1 Drug(s), documentation of trial, intolerance or contraindication to ONE Step 1 Drug is required
 - a. If yes, approve for 12 months
 - b. If no, clinical review required

Note:

Medication step therapy guidelines are used as a basis for making coverage decisions and do not serve as medical advice. Coverage of medications is subject to plan provisions. Additional coverage restrictions not listed in the guidelines may apply.



Topical Acne Agents Step Therapy Guidelines

Affected Medication(s)
• Clindagel 1% gel • Clindamycin phosphate 1% gel (clindagel generic) • Clindamycin phosphate-benzoyl peroxide 1.2-3.75% topical gel pump • Azelex (azelaic acid) 20% topical cream • Onexton (clindamycin phosphate-benzoyl peroxide) 1.2-3.75% topical gel pump • Veltin (clindamycin phosphate-tretinoin) topical gel • Clindamycin phosphate-tretinoin topical gel • Winlevi (clascoterone) topical cream • Ziana (clindamycin phosphate-tretinoin) topical gel
Step Therapy Requirements
Step 1 Drugs: • Tretinoin topical cream • Tretinoin topical gel • Neuac (clindamycin phosphate-benzoyl peroxide) 1.2-5% topical gel • Clindamycin phosphate-benzoyl peroxide 1.2-5% topical gel (Neuac generic) • Clindamycin phosphate-benzoyl peroxide 1-5% topical gel • Clindamycin phosphate-benzoyl peroxide 1-5% topical gel pump
Step Therapy Criteria
1. Prescription claim for TWO Step 1 Drug(s) within the past 180 days (Note: 90 days of claims history required for authorization) a. If yes, approve for 12 months b. If no, continue to #2 2. If no claim history of Step 1 Drug(s), documentation of trial, intolerance or contraindication to TWO Step 1 Drug is required a. If yes, approve for 12 months b. If no, clinical review required

Note:

Medication step therapy guidelines are used as a basis for making coverage decisions and do not serve as medical advice. Coverage of medications is subject to plan provisions. Additional coverage restrictions not listed in the guidelines may apply.



Topical Anti-Inflammatory Agents Step Therapy Guidelines

Affected Medication(s)
• Eucrisa (crisaborole) topical ointment • Vectical (calcitriol) ointment • Calcitriol ointment • Zonalon (doxepin) 5% cream • Prudoxin (doxepin) 5% cream • Doxepin topical cream
Step Therapy Requirements
Step 1 Drug(s): • Betamethasone dipropionate topical cream / lotion / ointment • Betamethasone dipropionate augmented topical cream / lotion / ointment • Betamethasone valerate topical cream / lotion / ointment • Calcipotriene cream • Calcipotriene ointment • Clobetasol propionate topical cream / ointment / solution / lotion • Desoximetasone topical cream / gel / ointment • Fluocinonide topical cream / gel / ointment / solution • Fluocinonide-E (fluocinonide-emollient base) topical cream • Halobetasol propionate topical cream / ointment • Tacrolimus topical ointment
Step Therapy Criteria
1. Prescription claim for TWO Step 1 Drug(s) within the past 180 days (Note: 90 days of claims history required for authorization) a. If yes, approve for 12 months b. If no, continue to #2 2. If no claim history of Step 1 Drug(s), documentation of trial, intolerance or contraindication to TWO Step 1 Drugs is required a. If yes, approve for 12 months b. If no, clinical review required

Note:

Medication step therapy guidelines are used as a basis for making coverage decisions and do not serve as medical advice. Coverage of medications is subject to plan provisions. Additional coverage restrictions not listed in the guidelines may apply.



Topical Vitamin A Derivatives Step Therapy Guidelines

Affected Medication(s)
• Akliel (trifarotene) topical cream • Altreno (tretinoin) lotion • Arazlo (tazarotene) topical lotion • Fabior (tazarotene) topical foam • Retin-A-Micro (tretinoin microspheres) topical gel • Retin-A-Micro Pump (tretinoin microspheres) topical gel • Tazarotene 0.05% topical cream • Tazarotene topical foam • Tazarotene topical gel • Tazorac (tazarotene) 0.05% topical cream • Tazorac (tazarotene) topical gel • Tretinoin gel micro 0.08% pump • Tretinoin microsphere topical gel • Tretinoin microsphere topical gel pump • Twynéo (tretinoin 0.1%-benzoyl peroxide 3%) topical cream
Step Therapy Requirements
Step 1 Drug(s): • Tazarotene 0.1% topical cream • Tretinoin topical cream • Tretinoin topical gel
Step Therapy Criteria
1. Prescription claim for TWO Step 1 Drug(s) within the past 180 days (Note: 90 days of claims history required for authorization) a. If yes, approve for 12 months b. If no, continue to #2 2. If no claim history of Step 1 Drug(s), documentation of trial, intolerance or contraindication to TWO Step 1 Drugs is required a. If yes, approve for 12 months b. If no, clinical review required

Note:

Medication step therapy guidelines are used as a basis for making coverage decisions and do not serve as medical advice. Coverage of medications is subject to plan provisions. Additional coverage restrictions not listed in the guidelines may apply.



Triptan Agents Step Therapy Guidelines

Affected Medication(s)

Step 2 Drug(s):

- Almotriptan malate oral tablet
- Eletriptan hydrobromide oral tablet
- Frova (frovatriptan succinate) oral tablet
- Frovatriptan succinate oral tablet
- Migranal (dihydroergotamine mesylate) nasal spray
- Dihydroergotamine mesylate nasal spray
- Relpax (eletriptan hydrobromide) oral tablet
- Rizafilm (rizatriptan benzoate) film
- Sumatriptan nasal spray
- Zolmitriptan nasal spray
- Zolmitriptan oral disintegrating tablet

Step 3 Drug(s):

- Onzetra Xsail (sumatriptan succinate) nasal powder
- Tosymra (sumatriptan) nasal spray
- Zembrace SymTouch (sumatriptan succinate) subcutaneous pen injector

Step Therapy Requirements

Step 1 Drug(s):

- Naratriptan HCl oral tablet
- Rizatriptan benzoate oral tablet
- Rizatriptan benzoate orally disintegrating tablet
- Sumatriptan succinate oral tablet

Step 2 Drug(s):

- Almotriptan malate oral tablet
- Eletriptan hydrobromide oral tablet
- Frova (frovatriptan succinate) oral tablet
- Frovatriptan succinate oral tablet
- Migranal (dihydroergotamine mesylate) nasal spray
- Dihydroergotamine mesylate nasal spray
- Relpax (eletriptan hydrobromide) oral tablet
- Rizafilm (rizatriptan benzoate) film
- Sumatriptan nasal spray
- Zolmitriptan nasal spray
- Zolmitriptan oral disintegrating tablet

Step Therapy Criteria

1. Is the request for a step 2 medication?
 - a. If yes continue to #2



- b. If no, continue to #4
- 2. Does the member have prescription claim for TWO Step 1 Drug(s) within the past 180 days? (Note: 30 days of claims history required for authorization)
 - a. If yes, approve Step 2 Drug for 12 months
 - b. If no, continue to #3
- 3. Does the member have documentation of trial, intolerance or contraindication to TWO Step 1 Drug?
 - a. If yes, approve Step 2 Drug for 12 months.
 - b. If no, clinical review required
- 4. Does the member have prescription claim for TWO Step 1 Drug(s) within the past 180 days? (Note: 90 days of claims history required for authorization)
 - a. If yes, continue to #6
 - b. If no, continue to #5
- 5. Does the member have documentation of trial, intolerance or contraindication to TWO Step 1 Drug?
 - a. If yes, continue to #6
 - b. If no, clinical review required
- 6. Does the member have prescription claim(s) for ONE Step 2 Drug(s) within the past 180 days? (Note: 30 days of claims history required for authorization)
 - a. If yes, approve step 3 drug for 12 months
 - b. If no, continue to #7
- 7. Does the member have documentation of trial, intolerance, or contraindication to ONE Step 2 Drug?
 - a. If yes, approve step 3 drug for 12 months
 - b. If no, clinical review is required

Note:

Medication step therapy guidelines are used as a basis for making coverage decisions and do not serve as medical advice. Coverage of medications is subject to plan provisions. Additional coverage restrictions not listed in the guidelines may apply.